ELC-401

N/A

Report date: 2024/11/13 15:02:23

Base Information

Drug NameELC-401
Drug Alias NameELC401
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulators
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesElicera Therapeutics AB
China Registration ClassN/A

Develop Information

Active CompaniesElicera Therapeutics AB
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A